MK-2206 2HCl

MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.

Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 370 In stock
USD 570 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

MK-2206 2HCl Chemical Structure

MK-2206 2HCl Chemical Structure
Molecular Weight: 480.39

Validation & Quality Control

Product Use Citation(156)

Customer Product Validation(16)

Quality Control & MSDS

Related Compound Libraries

MK-2206 2HCl is available in the following compound libraries:

Akt Inhibitors with Unique Features

  • Selective Akt Inhibitor

    CCT128930 AKT2-selective, IC50=6 nM.

  • Most Potent Akt Inhibitor

    AZD5363 Akt1, IC50=3 nM; Akt2, IC50=8 nM; Akt3, IC50=8 nM.

  • Akt Inhibitor in Clinical Trial

    Perifosine (KRX-0401) Phase III fro relapsed and refractory multiple myeloma.

  • Newest Akt Inhibitor

    AZD5363 Potent inhibitor of all isoforms of Akt (Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM, similar to P70S6K/PKA and lower activity towards ROCK1/2.

Product Information

  • Compare Akt Inhibitors
    Compare Akt Products
  • Research Area
  • Inhibition Profile

Product Description

Biological Activity

Description MK-2206 2HCl is a highly selective inhibitor of Akt1/2/3 with IC50 of 8 nM/12 nM/65 nM in cell-free assays, respectively; no inhibitory activities against 250 other protein kinases observed. Phase 2.
Targets Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
IC50 8 nM 12 nM 65 nM
In vitro MK-2206 is an allosteric inhibitor and is activated by the pleckstrin homology domain. MK-2206 inhibits auto-phosphorylation of both Akt T308 and S473. MK-2206 also prevents Akt-mediated phosphorylation of downstream signaling molecules, including TSC2, PRAS40 and ribosomal S6 proteins. [1] MK-2206 inhibits Ras wild-type (WT) cell lines (A431, HCC827, and NCI-H292) more potently when compared to Ras-mutant cell lines (NCI-H358, NCI-H23, NCI-H1299, and Calu-6). MK-2206 also shows synergistic responses in combination with cytotoxic agents such as erlotinib or lapatinib in lung NCI-H460 or ovarian A2780 tumor cells. [2] MK-2206 or siRNA-mediated Akt inhibition strongly activates autophagy in human glioma cells. However, eukaryotic elongation factor-2 (eEF-2) silencing suppresses MK-2206-induced-autophagy, with a promotion of apoptotic cell death. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity Description
NCI-H292M4X0cGN6fG:2b4jpZ{BCe3OjeR?=MVWzJO69VQ>?MV:3NkBpMV7EUXNQM4fxeWlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w
A431NIjIfGhMcW6jc3WgRZN{[Xl?NXu0dmJqPSEQvF2=NXHWOG1tPSCqNXraPW5ZTE2VTx?=MWTTeZBxemW|c3XzJJRp\SC|aXfuZYxqdmdib3[gRYt1KGGwZDDFdos>
HepG2NHvkR41EgXSxdH;4bYMhSXO|YYm=MYKxNEDPxE1?MknDNlQhcA>?NFTHbnJFVVORNHzCWY5U\W6|aYTpfoV{KHKnc3nzeIFvfCClZXzsd{B1dyC2aHWgZ5l1d3SxeHnjJIVn\mWldDDv[kB{d3KjZnXubYI>
Sk-Hep1MX3DfZRwfG:6aXOgRZN{[Xl?NWK1NXg3OTBizszNM3\5RVI1KGh?M2L4SGROW09?NYPC[HI2W2Wwc3n0bZpmeyC{ZYPpd5RidnRiY3XscJMhfG9idHjlJIN6fG:2b4jpZ{Bm\m[nY4Sgc4Yhe2:{YX\lcolj
OCUT1 cells harbored PIK3CA (H1047R+/+)MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3fRSFMh|ryPMVu1JIQ>MWDEUXNQNIDZT25KSzVyPUCuNVQh|ryP
K1 cells harbored PIK3CA (E542K+/+)MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\EUIpVOyEQvF2=NXruUlRKPSCmNEnOfY1FVVORM1;K[WlEPTB;MD61NkDPxE1?
FTC133 cells harbored PTEN (allele deletion and R130+)M4jx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIK2UJI{KM7:TR?=NYfNSVVWPSCmM3jmO2ROW09?M1PHOWlEPTB;MD6xPEDPxE1?
C643 cells harbored HRAS (G13R+/−)MnXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrxN{DPxE1?MlfUOUBlMlS0SG1UVw>?NUDwe285UUN3ME2wMlI4KM7:TR?=
Hth7 cells harbored NRAS (Q61R+/−)NWSyZZk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYf6dpluOyEQvF2=Mn\4OUBlM4e0N2ROW09?M1zjZ2lEPTB;ND61JO69VQ>?
TPC1 cells harbored RET/PTC1 rearrangementNGDTTJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4XFS|Mh|ryPNG[zZVQ2KGR?MX;EUXNQMVjJR|UxRTBwNUmg{txO
Hth74Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\LSlMh|ryPNH;ae2g2KGR?NXjB[IwzTE2VTx?=M3L5eWlEPTB;Mj6xPUDPxE1?
KAT18Mm\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUezV|Y6OyEQvF2=Mm[xOUBlMWfEUXNQNXvxZoRHUUN3ME20MlYzKM7:TR?=
SW1736MoDMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Moi5NVAxKM7:TR?=MV:1JIQ>MkHxSG1UVw>?MXLJR|UxRTR5LkW2JO69VQ>?
WRONFy2PJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPhdWROOTByMDFOwG0>NX7CcZE{PSCmMWrEUXNQMlSyTWM2OD5zMECwJO69VQ>?
TAD2NF7mSndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnLGNVAxOCEQvF2=MX[1JIQ>NUTpOoY3TE2VTx?=MVTJR|UxRjFyMECg{txO
LN229MUjBdI9xfG:|aYOgRZN{[Xl?NIm4eJgxNjVizszNMVm2NEBpM4\jV2ROW09?NUfjV5prSXWpbXXueJMh[XCxcITv[4VvcWNiZX\m[YN1eyCxZjDn[YZqfGmwaXK=
T98GMlnrRZBweHSxc3nzJGF{e2G7MUOwMlUh|ryPMn;zOlAhcA>?NGLGOVhFVVORM2\MfmF2\22nboTzJIFxd3C2b3flcolkKGWoZnXjeJMhd2ZiZ3XmbZRqdmmk
HC11M3q2U2Z2dmO2aX;uJGF{e2G7M37EN|ExKM7:TR?=M4[wXlI1KGh?NETIXoJFVVORMYjJcohq[mm2czFOtk1k[XOnaX6gZY5lKEGGUmCgd5lvfGinc3nz
MOLT-4NIXXO2JEgXSxdH;4bYMhSXO|YYm=Mo[0NVAh|ryPNV3JNVhPPDhiaB?=NXv3RY1MTE2VTx?=NGHBWJpKSzVyPUGuO-KBkc7:TR?=
CEM-RNVr0U5NHS3m2b4TvfIlkKEG|c3H5M4TPXVExKM7:TR?=MlviOFghcA>?NUjJcnhqTE2VTx?=MUjJR|UxRTNwM,MAje69VQ>?
CEM-SMoj0R5l1d3SxeHnjJGF{e2G7M3PDR|ExKM7:TR?=NHnpVY41QCCqNVnlOFdUTE2VTx?=M2e0TmlEPTB;NT6x5qCK|ryP
MOLT-4Mo\pSpVv[3Srb36gRZN{[Xl?NGj1PHMyOCEQvF2=M4W4clI1KGh?NGPFN49FVVORM1i3bmJtd2OtczDj[YxteyCrbjD0bIUhTzBxR{GgdIhie2Vib3[geIhmKGOnbHygZ5lkdGV?
MOLT-4M2j0NmZ2dmO2aX;uJGF{e2G7NYnWV2liPOLCid88US=>NY\4NWJ2PCCqMYDEUXNQMl;QTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{PBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz
CEM-RM4fDVWZ2dmO2aX;uJGF{e2G7MXm05qCK|ryPMYK0JIg>MoL5SG1UVw>?MkfOTY5kemWjc3XzJJRp\SCjbX;1cpQhd2ZiY3zlZZZm\CCOQ{TBM2ItKGFid3XscE1me3SjYnzpd4hm\CCjdYTvdIhi\3libXHyb4Vz
CEM-SNEXrdmJHfW6ldHnvckBCe3OjeR?=NHTSSGI16oDLzszNM13LVFQhcA>?MoTOSG1UVw>?NHHrOmtKdmO{ZXHz[ZMhfGinIHHtc5VvfCCxZjDjcIVifmWmIFzDOWEwSixiYTD3[YxtNWW|dHHicIl{cGWmIHH1eI9xcGGpeTDtZZJs\XJ?
HepG2 cellMU\LbY5ie2ViQYPzZZk>Mm\uNlAh|ryPNGX4cHIzPCCqM4DwPGROW09?MmHQSI94dnKnZ4XsZZRmeyC2aHWgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXA>?
HepG2 cellMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3nQN|MxKM7:TR?=MoTGNlQhcA>?NYS2NllOTE2VTx?=M1nPdmlvcGmkaYTzJINmdGxiZ4Lve5Rp
HepG2 cellNIC0SnJCeG:ydH;zbZMhSXO|YYm=Mkj2NlAh|ryPMYCyOEBpMoLRSG1UVw>?MV;JcoR2[2W|IHPlcIwh[XCxcITvd4l{
GEONWLJNGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUi3c2NZPTByIH7NNGrjcoY4OiCqMYnEUXNQMYDJcohq[mm2czDj[YxtKGe{b4f0bC=>
CNE-1Mk\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV2xNEDPxE1?MX[5OkBpNGjJ[nFFVVORMlftTWM2OD1{Lkm2JO69VQ>?
CNE-2NX;B[GR6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfxRoh4OTBizszNM4jIbFk3KGh?NVHhTHFuTE2VTx?=Mo\xTWM2OD12LkWzJO69VQ>?
HONE-1Mon2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXyxNEDPxE1?M4\sb|k3KGh?MkDESG1UVw>?MmSwTWM2OD1|LkO3JO69VQ>?
SUNE-1NH6zTI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYXQNJozOTBizszNM{fQeVk3KGh?M3vLZWROW09?MVnJR|UxRTBwNUKg{txO
CNE-2M3;hdGZ2dmO2aX;uJGF{e2G7NV3pb3E6OTBizszNMmTHOFghcA>?NXP1ZZFYTE2VTx?=MULJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy
HONE-1M2fMOmZ2dmO2aX;uJGF{e2G7M2PtXVExKM7:TR?=MWS0PEBpM2O0SmROW09?MVvJcoR2[2W|IHPlcIwh[3mlbHWgZZJz\XO2IHH0JGcy
NEC8M1nPZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;iTWM2OD1yLkC5OlUyKM7:TR?=
P12-ICHIKAWANV;JenBGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXTsemJpUUN3ME2wMlEyPjJizszN
MDA-MB-175-VIIMYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXLPbWJUUUN3ME2wMlE{PzN6IN88US=>
AsPC-1MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUnCemh2UUN3ME2wMlIzOTJ{IN88US=>
T47DM4XKVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2HNeWlEPTB;MD6yPFI2KM7:TR?=
HHM{m0b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnLyTWM2OD1yLkOwNlg{KM7:TR?=
MOLT-16NYqzPY1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmKwTWM2OD1yLkOwN|Ih|ryP
ES5MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUTCcHlzUUN3ME2wMlM1PDV3IN88US=>
RS4-11NWX4[lBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrSTWM2OD1yLkO0OlEh|ryP
KARPAS-45M2flVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYPJR|UxRTBwM{ezNlEh|ryP
NCI-H720MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHk[XZlUUN3ME2wMlM4Pjd7IN88US=>
H9MlnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPodmlKSzVyPUCuN|g5QDNizszN
EFM-19M2jjV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFP4OGFKSzVyPUCuOFQxOSEQvF2=
SBC-1MoSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXfJR|UxRTBwNESwN|Uh|ryP
A4-FukNFf3ZZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEPqe|VKSzVyPUCuOFY5PjhizszN
NCI-H1563MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn31TWM2OD1yLkS4NVg6KM7:TR?=
HCC1419NGfTNXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTBwNEi4PVIh|ryP
H-EMC-SSMmDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PGSmlEPTB;MD60PVk{QSEQvF2=
BHT-101M{POUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;5TWM2OD1yLkWyPVYyKM7:TR?=
IGROV-1MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnqzTWM2OD1yLkW1NlQ6KM7:TR?=
HGC-27NVjXNmY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXy5XHNmUUN3ME2wMlU3Pzh|IN88US=>
MDA-MB-361M2\Cdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTBwNUe3OlEh|ryP
KE-37NFnXXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4jWU2lEPTB;MD61PFI3KM7:TR?=
HCC70NYTLe3JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLYTWM2OD1yLkW5PFI4KM7:TR?=
LNCaP-Clone-FGCM3TtWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk\YTWM2OD1yLk[xNFQ5KM7:TR?=
HAL-01MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3Pse2lEPTB;MD62NlE{KM7:TR?=
HTNIfMSGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXzRUHJ5UUN3ME2wMlY{OjN7IN88US=>
MDA-MB-415M2L1PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHm4XWdKSzVyPUCuOlM3OjZizszN
NOS-1NWjrOmp3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXMOGxKSzVyPUCuOlM4OjNizszN
DU-145M2Dnd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDEW5l4UUN3ME2wMlY1PzR3IN88US=>
OCUB-MMmDlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXHvWGZXUUN3ME2wMlcxQTZ4IN88US=>
VA-ES-BJM17Y[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUiwZo86UUN3ME2wMlc{ODJ3IN88US=>
J-RT3-T3-5M3HHd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUfQZ2VUUUN3ME2wMlc1PDB|IN88US=>
MOLT-4NGXLXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWTo[5JmUUN3ME2wMlgxPTh{IN88US=>
NB7NFjrfotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEf1c4hKSzVyPUCuPFI1OTFizszN
L-363MkKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4TlcWlEPTB;MD64N|Q1OiEQvF2=
NKM-1MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVHJR|UxRTBwOE[yOVMh|ryP
HOP-92NUCzVmxnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\BeWlKSzVyPUCuPFczOjNizszN
OAW-42MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTpbXdKSzVyPUCuPFg4OiEQvF2=
HuO9MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvhS45KSzVyPUCuPVI4PTFizszN
MFE-280NUTnbGxMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXn0VYlpUUN3ME2wMlk3PDZ3IN88US=>
EM-2Moi5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWnWNFlsUUN3ME2wMlk4QTN7IN88US=>
NCI-H520MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWjJR|UxRTBwOUi1PVIh|ryP
LB2241-RCCNEXqdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVO5bVR1UUN3ME2wMlk6PzN2IN88US=>
SK-NEP-1NX;uPZF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnfITWM2OD1zLkG0OFg2KM7:TR?=
LXF-289MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTFwMUexOVYh|ryP
EPLC-272HNFH4fVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTFwMUeyOVYh|ryP
COLO-684M{jzPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml\vTWM2OD1zLkKzO|I2KM7:TR?=
ES1NGm2VFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2fyOmlEPTB;MT6yOFA3PSEQvF2=
DOHH-2MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3yWopMUUN3ME2xMlI5OjB|IN88US=>
CTB-1NXq4UJZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV71SYc4UUN3ME2xMlI5QTlizszN
G-401NHzocWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWLTfYV2UUN3ME2xMlI6Pzl3IN88US=>
LoVoM1jwTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{P2OmlEPTB;MT6zNlU{PCEQvF2=
Ramos-2G6-4C10MlGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH62dJpKSzVyPUGuN|M4ODFizszN
MFM-223MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2X3VGlEPTB;MT6zOFQ3OSEQvF2=
PA-1MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWD0XGJjUUN3ME2xMlM2OjZ3IN88US=>
697NF\UfphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWjLd5Y1UUN3ME2xMlM4PjF4IN88US=>
QIMR-WILM1zVb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnzJTWM2OD1zLkS5NVE3KM7:TR?=
HOSNGXzeoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXTJR|UxRTFwNEm1OVgh|ryP
DMS-273MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{T3[GlEPTB;MT61NVk2QSEQvF2=
ME-180MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LjfmlEPTB;MT61Olg6OSEQvF2=
HCC2218NHXjTmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnTLTWM2OD1zLk[4NlI2KM7:TR?=
CAL-54MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWLJR|UxRTFwN{GyOFIh|ryP
OMC-1M1nu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYHJR|UxRTFwN{S2O|ch|ryP
COR-L105NX\CPWlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYTlRWs5UUN3ME2xMlc6PzN5IN88US=>
BV-173MmHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jTdGlEPTB;MT64NVA4PCEQvF2=
RKOMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkTHTWM2OD1zLki3NVAyKM7:TR?=
SNU-387MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml;FTWM2OD1zLki4OFA3KM7:TR?=
SW1088NV;KRZZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTFwOUS2NFYh|ryP
Hs-578-TMn7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPsWZNKSzVyPUKuNVE1OzNizszN
OC-314NHHGUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYf6UYRyUUN3ME2yMlE2ODh4IN88US=>
RMG-INVn1W|dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH\jZpdKSzVyPUKuNVY{QThizszN
NCI-H1395NIq2XIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTJwMUiwPVEh|ryP
GAMGNXnjW2FWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYjubFJzUUN3ME2yMlI{QDR3IN88US=>
LB1047-RCCM3\mTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHUTWM2OD1{LkK0N|E4KM7:TR?=
MN-60Ml3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHXQV2RKSzVyPUKuNlk6OjNizszN
OAW-28M4O0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH3HemFKSzVyPUKuNlk6PTFizszN
NCI-H2228MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{CyUGlEPTB;Mj6zNVU2OiEQvF2=
ABC-1MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NETrUHRKSzVyPUKuN|MzPTNizszN
LS-513MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\CWmlEPTB;Mj6zN|Q5PCEQvF2=
KS-1NX\NWIt7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUjHeIZHUUN3ME2yMlM5OTlzIN88US=>
NB69MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGX4PXRKSzVyPUKuN|g6QDNizszN
VM-CUB-1M4HocWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4\xZmlEPTB;Mj6zPVA5OyEQvF2=
D-423MGMlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV7zNGlPUUN3ME2yMlQyODR2IN88US=>
EW-18NYrZOmd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NY\hNIN3UUN3ME2yMlQyQTN7IN88US=>
YH-13MknuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPIOGdKSzVyPUKuOFYyPTNizszN
T-24MmLkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4D4R2lEPTB;Mj60O|g5OSEQvF2=
ES8MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3zaR2lEPTB;Mj60PVI5PyEQvF2=
ES3M2PWPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XFUmlEPTB;Mj60PVc2QSEQvF2=
RXF393MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{fRSWlEPTB;Mj62NFQ5PyEQvF2=
RPMI-8226MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnWTWM2OD1{Lk[yPVU{KM7:TR?=
AGSM1PKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTJwN{KxN|ch|ryP
HCC1395MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVLJR|UxRTJwN{WxPFch|ryP
MV-4-11NX3KbmRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETqcG5KSzVyPUKuO|UzPjZizszN
A204NXrkeJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE[5cWpKSzVyPUKuPFM5PzJizszN
MCF7NH22UY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVnJR|UxRTJwOE[xNVch|ryP
SNU-423Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUjJR|UxRTJwOEmyOFIh|ryP
NCI-H1048NHqySpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUXL[nJsUUN3ME2yMlk3QDZ3IN88US=>
GR-STNX;COZpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NG\oN|hKSzVyPUOuNFQ3OTFizszN
EoL-1-M1zSc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnfsTWM2OD1|LkC3NFU5KM7:TR?=
HuH-7NEfJTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MluwTWM2OD1|LkC5OFY1KM7:TR?=
OS-RC-2NWTmSo0zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M165VmlEPTB;Mz6xNVE6KM7:TR?=
EW-3Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWfJR|UxRTNwMUm1Nlkh|ryP
NCI-H747M{LQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MV\JR|UxRTNwMkC2PVQh|ryP
EW-16MlTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTNwMkG4O|kh|ryP
DOKNHLuRXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M17yVWlEPTB;Mz6yNlg2QSEQvF2=
HCC2157MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHPrPXlKSzVyPUOuN|gyPzlizszN
OVCAR-3NH3ZRpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;JdmlEPTB;Mz60NFc5PiEQvF2=
NCI-H1623MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnXkTWM2OD1|LkSxNlI1KM7:TR?=
H4M37ZOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXPDbVlXUUN3ME2zMlQ2PjJ4IN88US=>
SW1710M4rmXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{m2e2lEPTB;Mz60OlY4QCEQvF2=
RT-112M1rXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MluyTWM2OD1|LkWyN|g5KM7:TR?=
DMS-114NGG5fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX3wVnRPUUN3ME2zMlYzOjd6IN88US=>
AN3-CAM2jxb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[2cm1KSzVyPUOuOlI1PTZizszN
KNS-62MnnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1rNUWlEPTB;Mz62N|M{QCEQvF2=
SJRH30MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PBUmlEPTB;Mz62PVEzOiEQvF2=
G-402NHnw[nVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnf4TWM2OD1|LkewO|EyKM7:TR?=
MHH-PREB-1MknqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXvJR|UxRTNwN{KwN|gh|ryP
P30-OHKNYH5UpE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIX3VoVKSzVyPUOuPFA6PzZizszN
RVH-421NVLMVYw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{jVfGlEPTB;Mz64NVc5QCEQvF2=
LU-134-ANWDWWVgzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVLJR|UxRTNwOEi0Nlgh|ryP
ECC10MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4\USGlEPTB;Mz65N|YzOiEQvF2=
TGWMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2LwNmlEPTB;ND6wNlMxPSEQvF2=
MLMANHTXTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2TicWlEPTB;ND6wNlk3PiEQvF2=
SCC-25MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUX6OIhqUUN3ME20MlA3PTZ4IN88US=>
TYK-nuM1HvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVX3[HF1UUN3ME20MlA6PTN2IN88US=>
LAMA-84NHr1b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjhNY9kUUN3ME20MlE1OTlzIN88US=>
Calu-3NYHvNGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETK[I9KSzVyPUSuNlQ1OTZizszN
NCI-H460MmnLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{nNfGlEPTB;ND6yOlQ1OyEQvF2=
EGI-1M3TISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUTJR|UxRTRwM{e3O|gh|ryP
NCI-H292M4XHcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVv4[lhuUUN3ME20MlM5OTR4IN88US=>
HCE-TM{DjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2rSNWlEPTB;ND60NVU4QSEQvF2=
EW-11MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTRwNEG4N|gh|ryP
ATN-1MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NI\SVYVKSzVyPUSuOFQ{ODRizszN
NB5NV64R5ZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTRwNUO2PVch|ryP
KLENET3ZVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUTTN5BNUUN3ME20MlcxOTl6IN88US=>
CAL-39MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1zCPGlEPTB;ND63NlE1PiEQvF2=
TI-73NGnYdpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmTuTWM2OD12LkiwOlA6KM7:TR?=
HO-1-N-1NH\0SpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVu5[4lJUUN3ME20Mlk1OiEQvF2=
786-0NHiwVY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmrVTWM2OD12Lkm0Olc{KM7:TR?=
SK-N-DZMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXTJR|UxRTRwOU[xOFIh|ryP
NCI-H446NEW2ZmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDYTWM2OD13LkKwNFA6KM7:TR?=
ETK-1MkjBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTVwMkGxOlUh|ryP
BT-20MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPlbFBMUUN3ME21MlIyOzV|IN88US=>
MEL-HOMmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{jqUGlEPTB;NT6zO|M{PiEQvF2=
CAL-27M3;nZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn;vTWM2OD13LkS2N|M6KM7:TR?=
SW872M2r2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1P0S2lEPTB;NT61PVQzQCEQvF2=
RPMI-2650MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXHJR|UxRTVwNk[xPVkh|ryP
PFSK-1M1O2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{fz[mlEPTB;NT63Nlc{OiEQvF2=
SF295NWLMbmJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mo[0TWM2OD13LkiwOlM{KM7:TR?=
BeckerNHfn[41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUfJR|UxRTVwOE[0O|Ih|ryP
Saos-2M{K4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXPJR|UxRTVwOE[1N{DPxE1?
SK-OV-3M4myV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVrJR|UxRTVwOUm4NVYh|ryP
VMRC-RCZMkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIHkVXJKSzVyPU[uNFg4PzNizszN
EW-22NVi4b4xZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVPJR|UxRTZwMUm2OFkh|ryP
BT-474NWfOfZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fR[GlEPTB;Nj6yN|Mh|ryP
BFTC-909NVfQb5B[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjxSHlYUUN3ME22MlMxOzR3IN88US=>
NB12Mn6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFrzVIdKSzVyPU[uN|kxPzFizszN
D-263MGM1LmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV[wTWhoUUN3ME22MlQ2OTZ7IN88US=>
SNB75NHzlTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVn1d3cxUUN3ME22MlYxOTR|IN88US=>
A704NFvYV4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnPOTWM2OD14Lk[zNFYh|ryP
NCI-H1693NVPKW2d5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4f0e2lEPTB;Nj62N|YxPCEQvF2=
LN-405NIjnTFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWDJR|UxRTZwN{m2O|Ih|ryP
CHL-1MlH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmDPTWM2OD14LkiwNFc6KM7:TR?=
A498MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mo\oTWM2OD14LkixPVYyKM7:TR?=
TE-12MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV\CV292UUN3ME22Mlg{QDF5IN88US=>
TE-6MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF21RYNKSzVyPU[uPVMxOzhizszN
AU565MnXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFPWSIZKSzVyPU[uPVY6PTdizszN
RDNVu2OHpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vISmlEPTB;Nj65PFI5PCEQvF2=
SW1463M{P4emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3:1O2lEPTB;Nz6xNVE3QCEQvF2=
LU-99ANH\EVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1fFUGlEPTB;Nz6xOFMzOiEQvF2=
NCI-H28MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2PmfGlEPTB;Nz6yPVI1KM7:TR?=
MC-IXCNWfncWZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYfJR|UxRTdwNEi1O|Yh|ryP
GP5dMYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LNUmlEPTB;Nz60PFc3PCEQvF2=
GB-1NV;BS|BKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1OxdWlEPTB;Nz61OFgxPCEQvF2=
CAL-33NEjCd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jKOWlEPTB;Nz62OlI{OyEQvF2=
MSTO-211HNIXtcppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\0Tm5nUUN3ME23MlY4OzN4IN88US=>
TE-5MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFraWFNKSzVyPUeuO|k{OzRizszN
D-566MGMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{OyXmlEPTB;OD6wOFQzQSEQvF2=
JVM-3M1i1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVLId2xIUUN3ME24MlE2OjZ6IN88US=>
T98GNV;odWtUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUHJR|UxRThwMUiwOlch|ryP
HCC1954NVyxUZloT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Moi1TWM2OD16LkS1NVA1KM7:TR?=
SF126NYCy[XRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnRbHNlUUN3ME24MlQ2QTN4IN88US=>
LB996-RCCM4K0TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRThwNUOyOVch|ryP
SKG-IIIaNHezVWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWXZXVhpUUN3ME24MlY{ODZ7IN88US=>
NCI-SNU-1NGTJSnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NULEb206UUN3ME24MlY1PjR|IN88US=>
LB771-HNCNXPMU|VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRThwNkS2PVYh|ryP
SCC-4M2TGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mk[yTWM2OD16Lk[4NlE6KM7:TR?=
CAMA-1MkL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVrJR|UxRThwN{exOFYh|ryP
D-502MGNHu5cZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRThwN{i2Nlkh|ryP
ESS-1NXHrZoU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlnDTWM2OD16Lki4O|A1KM7:TR?=
HEC-1MlnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M174d2lEPTB;OD64PVg3PiEQvF2=
NB10MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3\PTmlEPTB;OT6wNlIzPCEQvF2=
8505CMUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVTJR|UxRTlwMESyN|Ih|ryP
EFO-27NXHmV3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3;EdGlEPTB;OT6xOlQyOiEQvF2=
HNM{SxU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVPJR|UxRTlwMU[2Nlgh|ryP
DSH1M4T1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4GzO2lEPTB;OT6yNFg4KM7:TR?=
NBsusSRNGrMNnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmHaTWM2OD17LkK3OFAzKM7:TR?=
LS-123Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlzrTWM2OD17LkOxO|YyKM7:TR?=
SHP-77NIPhfldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoLGTWM2OD17LkO5PVM2KM7:TR?=
ACNM{ntVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFr1VIhKSzVyPUmuOVMzPzdizszN
U251M4HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4Pm[mlEPTB;OT62OVU1PCEQvF2=
A431NEC3O3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXHJR|UxRTlwOECyN|gh|ryP
5637NGnOXYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTlwOES5PFQh|ryP
MDA-MB-157MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIT5R3JKSzVyPUmuPVI5PzhizszN
A101DMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ftNmlEPTB;OT65PVk4PCEQvF2=
YKG-1MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnHTTWM2OD1zMD6yNFA3KM7:TR?=
LAN-6NUj3WWZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFXCR2ZKSzVyPUGwMlIyPjRizszN
OVCAR-5NXH1T3VkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnLvTWM2OD1zMD6yOFM{KM7:TR?=
A549MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1ToT2lEPTB;MUCuN|k4OyEQvF2=
no-11MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTFyLkSzOVMh|ryP
SF539MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWfDVVNiUUN3ME2xNE46ODRzIN88US=>
A388NVPOTFB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MofyTWM2OD1zMT6zPFk4KM7:TR?=
DELMn\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3RWJVPUUN3ME2xNU41OjRizszN
SW954MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTFzLkS2Olgh|ryP
TK10NU\kcIZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTjTWM2OD1zMT61NlcyKM7:TR?=
SW756M17peGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4KzVWlEPTB;MUGuOVI6PCEQvF2=
PC-3M1HldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPvTWM2OD1zMT61O|Y1KM7:TR?=
ONS-76NET2coVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLx[WxKSzVyPUGxMlY{PiEQvF2=
A427M3;sXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnXVTWM2OD1zMT63NFk{KM7:TR?=
MEG-01M4TFOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NE\TW|RKSzVyPUGxMlc2ODlizszN
BB30-HNCNXLISWM1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTFzLke5PFIh|ryP
NCI-H1299NV;o[3VjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3Hn[GlEPTB;MUGuPFA6OyEQvF2=
GCTMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1\mdWlEPTB;MUGuPFIzQCEQvF2=
D-247MGM4faWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWPJR|UxRTFzLkm2OlMh|ryP
CFPAC-1MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M160TmlEPTB;MUGuPVc5OiEQvF2=
EKVXM1fWfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlnxTWM2OD1zMj6wN|E{KM7:TR?=
CAL-51MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWXUZZdCUUN3ME2xNk4xPzF4IN88US=>
BB49-HNCNXPTfJZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn35TWM2OD1zMj6xNVc4KM7:TR?=
RPMI-7951MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlf6TWM2OD1zMj6xPFU1KM7:TR?=
RH-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm[0TWM2OD1zMj6yNVg1KM7:TR?=
BCPAPM1;STWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rES2lEPTB;MUKuOFc1QSEQvF2=
GCIYMkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTF{LkWyNFkh|ryP
KNS-81-FDM4jibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoLSTWM2OD1zMj61PFY6KM7:TR?=
KYSE-140NUTUZlR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH;YNmpKSzVyPUGyMlg2QTVizszN
Ca-SkiNYK2Z4w6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDVXYpYUUN3ME2xNk46ODRzIN88US=>
TGBC1TKBNXHXW3NOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjRTWM2OD1zMj65NVE2KM7:TR?=
HCC1187NE\nZo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHTLT5lKSzVyPUGzMlE6OTJizszN
SJSA-1NYK0TnAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUPJR|UxRTF|LkKzNlch|ryP
CTV-1MlvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTJTWFKSzVyPUGzMlM1PSEQvF2=
WM-115M4fHOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYfJR|UxRTF|Lk[0PFMh|ryP
CHP-212MlHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnzGTWM2OD1zMz65O|M6KM7:TR?=
SCC-15M4fvfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDPTWM2OD1zMz65O|c2KM7:TR?=
BPH-1M{HaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH:0cppKSzVyPUG0MlE3PjRizszN
SW780M2LXVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2K0NWlEPTB;MUSuOVAzPSEQvF2=
NCI-H2291MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFTiZ2xKSzVyPUG0MlU5PzhizszN
JEG-3MkmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUnXfG8yUUN3ME2xOE43OzJ4IN88US=>
CAL-120MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2KzcmlEPTB;MUSuO|AzPyEQvF2=
NCI-H23MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MX;JR|UxRTF2Lke5PVch|ryP
MS-1MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3TVUWlEPTB;MUSuPVYyOSEQvF2=
PC-14NVrp[lVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYT4WXdZUUN3ME2xOE46PjV2IN88US=>
D-283MEDNGfCNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWm3ZmM5UUN3ME2xOU4xOTFzIN88US=>
OE19Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV;JR|UxRTF3LkG1OFEh|ryP
CAS-1MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGLZNoxKSzVyPUG1MlQyQDRizszN
NCI-H727NGLPZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTF3LkSyNlEh|ryP
SiHaNV72cFVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{fKOGlEPTB;MUWuO|U6PCEQvF2=
BFTC-905M2jK[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHmzUllKSzVyPUG1Mlc3QTRizszN
MDA-MB-453MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVzJR|UxRTF4LkG2OFIh|ryP
HuP-T3M1Pa[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF4Lk[zO|Mh|ryP
SK-LU-1MlTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGCyUopKSzVyPUG2MlY6PTZizszN
Detroit562MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvqO4VmUUN3ME2xOk44OzF6IN88US=>
HCC1569MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTF4LkizN|ch|ryP
SK-MES-1MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2O2fGlEPTB;MU[uPFQyQSEQvF2=
BB65-RCCMXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEfCe5RKSzVyPUG3MlA1PzlizszN
LOXIMVINFrueGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2D2fmlEPTB;MUeuNFcxPyEQvF2=
SW1783NXTkSXdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXrTWM2OD1zNz6xNlgh|ryP
NH-12MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVP5NZBSUUN3ME2xO{4{OzB|IN88US=>
UACC-257MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEjrNZpKSzVyPUG3MlU2OTJizszN
KOSC-2NUXtV29rT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1XTNGlEPTB;MUeuOlc2PyEQvF2=
KG-1MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fzV2lEPTB;MUeuOlk{PyEQvF2=
M059JMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1vvOmlEPTB;MUeuO|A{KM7:TR?=
MHH-NB-11M1XNdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MY\JR|UxRTF5Lkm2O|Mh|ryP
EW-1NEXO[5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkLQTWM2OD1zOD6xN|gzKM7:TR?=
CAL-85-1M{fDWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NH\zfGNKSzVyPUG4MlI{PTdizszN
639-VMmnqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn;KTWM2OD1zOD6zN|U1KM7:TR?=
C32MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4XmNmlEPTB;MUiuOFczPyEQvF2=
KM-H2MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVrJR|UxRTF6LkWyN|Ih|ryP
A253NFi1NJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH3kdXlKSzVyPUG4MlczQDZizszN
NCI-N87MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF3JR45KSzVyPUG4MlkxODhizszN
8-MG-BANYPt[3JxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoLTTWM2OD1zOT6wOlQ3KM7:TR?=
GI-ME-NNXTyZ|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF32Nm1KSzVyPUG5MlE2PDZizszN
8305CMk\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWDJR|UxRTF7LkKyPFYh|ryP
TE-8NF;o[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{SzUGlEPTB;MUmuN|AzPCEQvF2=
KYSE-270NHrtdlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4K0eWlEPTB;MkCuNFIyPyEQvF2=
HL-60MlK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXnJR|UxRTJyLkC5OFEh|ryP
Mo-TM{LH[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJyLkG2OlUh|ryP
NCI-H1355M4XHWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTJyLkOzO|Qh|ryP
HT-1080MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHL5PWRKSzVyPUKwMlU1QTdizszN
MIA-PaCa-2M2[5NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXjJR|UxRTJyLk[4PFMh|ryP
NCI-H441NHu3NY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJyLkezO|kh|ryP
LCLC-97TM1NGDmSYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTJyLkixN|Qh|ryP
HT-3MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFvqbVZKSzVyPUKxMlU3OzFizszN
22RV1Ml72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVvZbmRVUUN3ME2yNU42Pjh3IN88US=>
LK-2Mmr4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTJzLkW5OVMh|ryP
CW-2NVXFPJBwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJzLk[wOlkh|ryP
KYSE-510Ml\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlLZTWM2OD1{MT62NFk2KM7:TR?=
CGTH-W-1MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnH6TWM2OD1{MT63NVY3KM7:TR?=
NCI-H661Mn;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJ{LkCzOEDPxE1?
KU-19-19MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFnadoVKSzVyPUKyMlE3QTdizszN
NCI-H2122MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV7JR|UxRTJ{LkK0N|Ih|ryP
NCI-H526M3TOZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;XTWM2OD1{Mj6zPFk2KM7:TR?=
NCI-H1650NUDuNpBFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnTwTWM2OD1{Mj63OlQh|ryP
AM-38NWewdWJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LhcGlEPTB;MkKuPFY5QSEQvF2=
NCI-H2405NHfTOnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\sWmlEPTB;MkOuNlU{OyEQvF2=
M14MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzIOVM1UUN3ME2yN{41ODh6IN88US=>
ES4M{SzN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWrGWWJoUUN3ME2yN{41OjN{IN88US=>
DJM-1NEPaN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV[0dHdNUUN3ME2yN{42OjN2IN88US=>
S-117MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoD1TWM2OD1{Mz63OlUyKM7:TR?=
MZ2-MELNXfRRnc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml;vTWM2OD1{Mz63O|U6KM7:TR?=
SK-MEL-2NXn4eIVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIH6WIpKSzVyPUKzMlgyOzNizszN
HCC1806MkLQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVXJR|UxRTJ|Lki3NFkh|ryP
NMC-G1NEHybYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfRRYtwUUN3ME2yOE4zOjJ4IN88US=>
DK-MGNIfQV3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH\oUnJKSzVyPUK0MlI6PCEQvF2=
SK-N-FIMlyxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnOyTWM2OD1{ND6zN|AzKM7:TR?=
KINGS-1MnnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MW\JR|UxRTJ2LkS4O|Qh|ryP
HCC2998MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1jlXmlEPTB;MkSuOFg5PSEQvF2=
ALL-POMlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mo\FTWM2OD1{ND62NVkh|ryP
MPP-89NHzhWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{j6[WlEPTB;MkWuNFQ2QCEQvF2=
NCI-H2342MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NX;WbmNjUUN3ME2yOU4yQTV|IN88US=>
TE-1MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3rQNGlEPTB;MkWuN|U3OyEQvF2=
RH-18NUfYW2ZJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3T4OmlEPTB;MkWuOVkyQCEQvF2=
HT-1376NFPyO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEnTcYJKSzVyPUK1MlY1PjVizszN
U-2-OSM1W3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYLJR|UxRTJ3Lk[4PFgh|ryP
BT-549NFnZRY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LyT2lEPTB;MkWuPVAyOSEQvF2=
NCI-H1755NHjITndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{XIfWlEPTB;MkWuPVk1PSEQvF2=
EW-13MlTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV[3R|d3UUN3ME2yOk4xOjd2IN88US=>
NB13NXPpTXA1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnrzTWM2OD1{Nj6wPVQ6KM7:TR?=
NUGC-3M1n5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTJ4LkKxNFMh|ryP
GMS-10M1TwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoDJTWM2OD1{Nj6yN|U{KM7:TR?=
CHP-134M4jrdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVrsU5doUUN3ME2yOk4{QDZ5IN88US=>
SW962NVfQVIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWHwRVNrUUN3ME2yOk42ODJzIN88US=>
SNU-449NGXFNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{DF[2lEPTB;MkeuNFgxOyEQvF2=
HuP-T4MnrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEjkZ5hKSzVyPUK3MlA5PzlizszN
SW948M2C1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{PMSGlEPTB;MkeuNVM1PCEQvF2=
NCI-H226MnrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWrJR|UxRTJ5LkS1O|gh|ryP
SK-PN-DWMlXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWjJR|UxRTJ5Lk[wNVIh|ryP
GI-1Ml7hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkLtTWM2OD1{Nz63NlEh|ryP
CAL-12TMojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPlTWM2OD1{OD6xNVEzKM7:TR?=
YAPCNHLx[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJ6LkK1OlQh|ryP
SNU-C2BMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3K5UmlEPTB;MkiuNlk3PCEQvF2=
RCC10RGBNWH0NYZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV;JR|UxRTJ6LkW0NVch|ryP
ES7NXHmfnhqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn33TWM2OD1{OT6xOFY2KM7:TR?=
PANC-03-27NUHWPHpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3HuO2lEPTB;MkmuOFQ1KM7:TR?=
ES6MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4DXemlEPTB;MkmuPFE2PyEQvF2=
HT-1197NHzSR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1LhWWlEPTB;M{CuNFU6QCEQvF2=
ZR-75-30MmjIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEPWSmxKSzVyPUOwMlI{QDNizszN
DBNHnTcWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3rFW2lEPTB;M{CuOFk1OiEQvF2=
OCI-AML2MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTNzLkC2PUDPxE1?
NCI-H2170MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYLKUllDUUN3ME2zNU45PTF4IN88US=>
IST-MES1MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHERllOUUN3ME2zNk4zQDl5IN88US=>
769-PM1HNc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWC2eWlHUUN3ME2zNk4{PjRzIN88US=>
COR-L23MoDwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXS3[XFkUUN3ME2zNk46ODd|IN88US=>
SW626M4TlT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWrJR|UxRTN|LkG3O|Yh|ryP
LU-139MnnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NInHfVZKSzVyPUOzMlY3ODVizszN
HT-144NHq2W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlnGTWM2OD1|Mz64OlMh|ryP
CaR-1NUT0c4lST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGf2[FBKSzVyPUOzMlk5OjJizszN
OE33NWDQTGZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTN2LkK4OVUh|ryP
COLO-800MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXTNboJiUUN3ME2zOE4{PjR5IN88US=>
NB14MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGTMXlhKSzVyPUO0MlQ3QDRizszN
KURAMOCHIMYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTN4LkGxPVgh|ryP
SW48M3rNW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDDO|AyUUN3ME2zOk4zPDd2IN88US=>
DaoyNHKzSYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDYTWM2OD1|Nj62OVM5KM7:TR?=
TGBC24TKBM1\KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYDROm5DUUN3ME2zOk43PyEQvF2=
DU-4475NUe5UHdTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MojoTWM2OD1|Nj65NFM{KM7:TR?=
SW1417MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3TXVmlEPTB;M{iuNFU2OiEQvF2=
EFO-21NXH6elhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTN6LkmzOFkh|ryP
MG-63NEj6OJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;aPY92UUN3ME2zPU4{PDJ2IN88US=>
LC-2-adMnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3s[3lEUUN3ME2zPU42PTF{IN88US=>
NOMO-1NFXjfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjOTWM2OD1|OT64Nlc1KM7:TR?=
COLO-741MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV3JR|UxRTRyLkGzNFQh|ryP
BxPC-3MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3PuOGlEPTB;NECuOVY5PiEQvF2=
HSC-2M{fBd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUHJR|UxRTRyLkmxNVMh|ryP
UMC-11Mm[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NI[4WJFKSzVyPUSxMlI3OyEQvF2=
HCC1937MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4nD[WlEPTB;NEKuO|g1OyEQvF2=
Calu-6NFnGPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlHqTWM2OD12Mz6yN|gzKM7:TR?=
NCI-H1573MlHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWTJR|UxRTR|LkO0O|ch|ryP
SK-N-ASMmjDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYHTXIY2UUN3ME20N{43ODF7IN88US=>
PSN1M2j0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFjIOG1KSzVyPUS1MlI2PDhizszN
TE-11MmmyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnHOTWM2OD12NT60PFQzKM7:TR?=
NCI-H1155Mn3iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnL4TWM2OD12NT64PVY4KM7:TR?=
KM12Mkj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFTwU3FKSzVyPUS1MlkxPzZizszN
RO82-W-1NVrzVYVnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHvCeXJKSzVyPUS2Mlk5OjJizszN
SW1573NILTWlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUToR44xUUN3ME20O{4{PzN4IN88US=>
CAKI-1MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYjJR|UxRTR6LkK4OFUh|ryP
U-118-MGMn\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTR6LkO3NFIh|ryP
KYSE-520M4XVTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXTJR|UxRTR6LkSwNVYh|ryP
HT55MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1i1dGlEPTB;NEmuNVQ4PCEQvF2=
ChaGo-K-1NFTsOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mk[1TWM2OD12OT60O|k{KM7:TR?=
IA-LMNGj5PJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnntTWM2OD13ND62N|IzKM7:TR?=
UACC-62MofQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWjvO41UUUN3ME21OU4yODR4IN88US=>
MKN7Mn:wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjYTWM2OD13Nj6wNlg2KM7:TR?=
HPAF-IIMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlvLTWM2OD13Nj60NFc{KM7:TR?=
NTERA-S-cl-D1MlO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MonrTWM2OD13Nz63O|gh|ryP
FTC-133MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\HfJRKSzVyPUW4MlA6PjlizszN
MHH-ES-1MonvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXrJR|UxRTV6LkS4NVQh|ryP
JVM-2NHjWWHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M4nnc2lEPTB;NUiuPVUxPiEQvF2=
TCCSUPNWrnWGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2G2[2lEPTB;NUmuOVI4QSEQvF2=
COLO-824NW[0SYZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3vFR2lEPTB;NkCuNFcyQSEQvF2=
647-VNXHDWXNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXHJR|UxRTZyLkGzOFch|ryP
HD-MY-ZNXHBdWliT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWXscIRjUUN3ME22NE42Ojl2IN88US=>
LS-411NNH7vWohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYLJR|UxRTZzLkO5NFMh|ryP
NCI-H596Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MlW5TWM2OD14Mj63OFk3KM7:TR?=
C-33-AM1PDbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXLJR|UxRTZ2LkC5OVch|ryP
BHYMUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVvJR|UxRTZ2LkGyOFUh|ryP
KGNM325bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NIXQSppKSzVyPU[0MlU2OTRizszN
NCI-H1092NVPpeVFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVXJ[phlUUN3ME22OU4xODl3IN88US=>
MZ1-PCMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInpe5FKSzVyPU[1MlU3PDlizszN
LB831-BLCMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmnTTWM2OD14NT64OFgyKM7:TR?=
SW620NYDlcnNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXrJR|UxRTZ4LkKwN|kh|ryP
HuO-3N1NYPNUZYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkX6TWM2OD14OD6zNlM5KM7:TR?=
SK-HEP-1NVflNGM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LlT2lEPTB;NkmuPVQ5PiEQvF2=
LCLC-103HMYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1rHRmlEPTB;N{CuOlcxPSEQvF2=
KYSE-70NX65XYlMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX;JR|UxRTdyLke4N|Uh|ryP
MewoMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIHFVoVKSzVyPUexMlUxPSEQvF2=
COLO-668MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPzUndNUUN3ME23NU45PDVzIN88US=>
NCI-H522MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUPJR|UxRTd{LkO0NVMh|ryP
NCI-H1437MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG[0OlZKSzVyPUe0MlQxPDhizszN
U-266MnrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TMS2lEPTB;N{WuOFUyPiEQvF2=
MC116NEHaXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTd3LkW3NFgh|ryP
PANC-10-05M4THe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{Dj[GlEPTB;N{euOFI1OyEQvF2=
KYSE-180NWPpPVViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFfURmpKSzVyPUe3MlU1PTRizszN
JARNHi0e|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mkn1TWM2OD15OT6wOVQ3KM7:TR?=
CAL-62NWnKWnp{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvpOVdrUUN3ME24NE4xQTVizszN
A3-KAWMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRThyLkKxOVQh|ryP
PANC-08-13NWTTNIRyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUXJR|UxRThzLkG3Olgh|ryP
HSC-3M4jHPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHHNd4FKSzVyPUizMlMxPzFizszN
HTC-C3NF;mOYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NV6xVHhHUUN3ME24N{41PzB{IN88US=>
KY821M4K3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVW2XmxSUUN3ME24OE4xQDl{IN88US=>
DoTc2-4510Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{PJZmlEPTB;OESuNlE5PSEQvF2=
NCI-H1581MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRTh3LkS2OFEh|ryP
KARPAS-299MnzWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV\Ne3I2UUN3ME24Ok4yQTd5IN88US=>
IST-MEL1NWjWNWVoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUDJR|UxRTh4Lki4O|Ih|ryP
KP-N-YSNVjO[oFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHjZ[W1KSzVyPUi5MlkxOjhizszN
KYSE-410NFLLTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWnC[pFXUUN3ME25NU41ODR{IN88US=>
TE-10M3vhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4i0TmlEPTB;OUGuOVYyOSEQvF2=
SK-MEL-1NFvxSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnvlTWM2OD17Mj65NVA3KM7:TR?=
COLO-792NXXwWWtnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYPJR|UxRTl3LkK1OlQh|ryP
SCHMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHBW3N3UUN3ME25Ok4{QDd5IN88US=>
NCI-H1792NX\2RlZMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXfudo5UUUN3ME25Ok45QTl{IN88US=>
NCI-H2029M2rsNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYHoZ3V2UUN3ME25Ok46PTZ4IN88US=>
SW684NF;WNopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVHJR|UxRTl6Lk[2OVQh|ryP
NCI-H209M37DR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEH1eZVKSzVyPUGwNE4yOjFizszN
HLEM{\YRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M4DXbGlEPTB;MUC1MlI5OiEQvF2=
GOTOMleyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPpTWM2OD1zMEeuO|c4KM7:TR?=
NCI-H1793Mnf5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4XuOWlEPTB;MUC5MlI5KM7:TR?=
D-392MGMYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlfpTWM2OD1zMUeuN|k5KM7:TR?=
SW1990Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF{MD65OVEh|ryP
ML-2MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NIriUplKSzVyPUGyNU43PzZizszN
NCI-H2452MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHKzbVRKSzVyPUGyNk4zOSEQvF2=
SK-MEL-30MknhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NX3EbW5yUUN3ME2xNlMvOjR2IN88US=>
SN12CM4DmdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfpSWhKSzVyPUGyOE4yPzZizszN
NCI-H1770MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MV7JR|UxRTF{NT61NVQh|ryP
SF268NYfKO|FlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIfZOmpKSzVyPUGyOk4yPThizszN
BALL-1MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFrYWIRKSzVyPUGyOk4zOyEQvF2=
COLO-679MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEH5TFhKSzVyPUGyOk44PTNizszN
A2780MofXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUXJR|UxRTF{OD65PFgh|ryP
NCI-H1651NUHvUFE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF|MT6yOFMh|ryP
NCI-H2087MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF7tOWhKSzVyPUGzNU41QDNizszN
U-87-MGNU\rSGNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoTnTWM2OD1zM{OuOlA1KM7:TR?=
LB2518-MELM4LUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTF|NT65PVMh|ryP
HCT-116MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2DCXWlEPTB;MUO3MlIyPyEQvF2=
Ca9-22MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVLJR|UxRTF|OT64N|Mh|ryP
COR-L88NXPQbohWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mn;WTWM2OD1zNEKuNVQh|ryP
CP50-MEL-BMV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEThRVFKSzVyPUG0OE42ODFizszN
OVCAR-8NFP3e2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{\YRmlEPTB;MUS1MlY{PiEQvF2=
SK-MEL-3NWLoOo1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXPJR|UxRTF2Nz64O|gh|ryP
GT3TKBM3Tmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{C2emlEPTB;MUS5MlkzQCEQvF2=
KYSE-450NF76c2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV\JR|UxRTF3MT61N|kh|ryP
CAPAN-1Mn\IS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF\sSGxKSzVyPUG1N{4xPjRizszN
BENM3;LR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3LVUGlEPTB;MUWzMlkzQCEQvF2=
NCI-H1304NUXkbpJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTF3ND62PVQh|ryP
KU812NGPldndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHjVW3VKSzVyPUG1PE43PzRizszN
Capan-2MkP1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2j1PWlEPTB;MU[wMlU2OyEQvF2=
A673MkCyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3f5RWlEPTB;MU[xMlcxPSEQvF2=
SASMWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3v2b2lEPTB;MU[yMlY4QCEQvF2=
NYMkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1fIZWlEPTB;MU[1MlMyPCEQvF2=
HCE-4MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXvJR|UxRTF4Nj64OFUh|ryP
MDA-MB-231M4LwSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkDGTWM2OD1zN{euOVA{KM7:TR?=
no-10Mlm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH7sXopKSzVyPUG3PE4yOzRizszN
MZ7-melM3fkcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NI\GTIhKSzVyPUG3PE41PjdizszN
NCI-H82NF7yNFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV;JR|UxRTF6MD6xOlUh|ryP
CAL-72NHvrPGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIrJXlNKSzVyPUG4OU4xPTRizszN
NCI-SNU-5NHr2fFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXXJR|UxRTF6Nj64OEDPxE1?
OVCAR-4MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYfQcJNLUUN3ME2xPFgvOzN|IN88US=>
SCC-9NYD4S|loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTF7MTFOwG0>
KYSE-150NV\DbItxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVLEVWdCUUN3ME2xPVEvQDh6IN88US=>
HT-29MmGxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M135Z2lEPTB;MkCxMlIyOiEQvF2=
COLO-678NInvNHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUTJR|UxRTJyMT60OUDPxE1?
NCI-H650MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLjTWM2OD1{MEKuNVA{KM7:TR?=
HuCCT1MkTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LEVmlEPTB;MkC0MlIxQCEQvF2=
SW1116NWX5cYxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJyNz6wO|ch|ryP
DBTRG-05MGNYTRTGRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXzJR|UxRTJyNz65NFkh|ryP
SW982M176Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXHJR|UxRTJyNz65OFgh|ryP
RCM-1MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV;5VFVPUUN3ME2yNVQvPzZ{IN88US=>
COLO-320-HSRMoT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4PqSGlEPTB;MkG2MlEzPSEQvF2=
KNS-42M4OyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3nLVWlEPTB;MkG2MlU4PCEQvF2=
C2BBe1MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4LRcmlEPTB;MkOxMlkxPSEQvF2=
CCRF-CEMMX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYPJR|UxRTJ2Mz63PVUh|ryP
SH-4NY\ZPWV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mon2TWM2OD1{NE[uNFkh|ryP
LS-1034NHrVNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NEXEVnhKSzVyPUK0Ok4zPjZizszN
NCI-H2347NFfj[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFvKeoRKSzVyPUK0O{44OTNizszN
RPMI-8866MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYnJR|UxRTJ2OT6yO{DPxE1?
GAKM2LQbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGq1PHdKSzVyPUK1N{4xODJizszN
NB6NHfpXlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkDUTWM2OD1{N{CuNUDPxE1?
COLO-680NNUK1S2FLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NI\UPYxKSzVyPUK3Nk42OjdizszN
RERF-LC-MSNXrHOW1sT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYfwOndGUUN3ME2yO|YvODB5IN88US=>
TGBC11TKBNV65cI9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJ5OD6xO|gh|ryP
C8166NULEVoNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRTJ5OD61NFYh|ryP
HDLM-2MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3T4W2lEPTB;Mkm0MlQxQSEQvF2=
IGR-1NULkVoRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MorPTWM2OD1{OUWuOlU6KM7:TR?=
FADUMX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUX4TlZkUUN3ME2yPVcvPTFizszN
L-428M4fhbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXnJR|UxRTJ7Nz62NVYh|ryP
LU-65MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYfJR|UxRTNyND6zNkDPxE1?
HELM33Xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYTJR|UxRTNyOT65PFMh|ryP
NCI-H810NH3ORXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NILPfotKSzVyPUOxNE42PyEQvF2=
C3AMXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmXxTWM2OD1|MUGuPFAzKM7:TR?=
NCI-H630MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlTtTWM2OD1|M{KuNlk1KM7:TR?=
KP-N-YNNEf0RmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIr6T|VKSzVyPUO0NU4yOjNizszN
MOLT-13NETsT4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFjLe29KSzVyPUO0Nk4{OjZizszN
NCI-H1993NWLwSWpOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWnNb2FtUUN3ME2zOFIvOzZ3IN88US=>
BE-13NVHnO4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEP0SJVKSzVyPUO0OE4yPjdizszN
IST-SL1NV75TJo4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Mke0TWM2OD1|NEeuOFAyKM7:TR?=
TE-9MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M{LYNWlEPTB;M{[zMlU5QSEQvF2=
LU-135NYnZUWtDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MknDTWM2OD1|NkeuNFM2KM7:TR?=
T84NEPuTWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NH7XeItKSzVyPUO3OE44OTJizszN
K-562NGfiSm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfsTWM2OD1|OEOuN|Yh|ryP
SBC-5NXHvUnl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NH7Pb4VKSzVyPUO4Ok46QDVizszN
NB17NET5O2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2rvW2lEPTB;M{myMlU6PiEQvF2=
NCI-H2052NIi5TXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{TNT2lEPTB;M{m4MlQ4OiEQvF2=
HCC38MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXrTRZVVUUN3ME20NFEvPTl|IN88US=>
NCI-H69M3\yOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnjwTWM2OD12NEGuNFg{KM7:TR?=

... Click to View More Cell Line Experimental Data

In vivo MK-2206 shows 60% TGI and inhibits more than 70 % of phospho-Akt1/2 (T308 and S473) in A2780 ovarian cancer xenografts at a dose of 240 mg/kg. [1] MK-2206 exhibits significant antitumor activity in NCI-H292 xenograft in combination with erlotinib or lapatinib. [2]
Features The first allosteric small molecule inhibitor of Akt to enter clinical development.

Protocol(Only for Reference)

Kinase Assay: [4]

Akt kinases assay Akt kinases are assayed by a GSK-derived biotinylated peptide substrate. The extent of peptide phosphorylation is determined by Homogeneous Time Resolved Fluorescence (HTRF) using a lanthanide chelate (Lance)-coupled monoclonal antibody specific for the phosphopeptide in combination with a streptavidin-linked allophycocyanin (SA-APC) fluorophore which will bind to the biotin moiety on the peptide. When the Lance and APC are in proximity, a non-radiative energy transfer takes place from the Lance to the APC, followed by emission of light from APC at 655 nm. Working Solution: 100X protease inhibitor cocktail (PIC): 1mg/mL benzamidine, 0.5 mg/mL pepstatin, 0.5 mg/mL leupeptin, 0.5 mg/mL aprotinin; 10X assay buffer: 500 mM HEPES, pH7.5, 1% PEG, 16.6 mM EDTA, 1 mM EGTA, 1% BSA, 20 mM 9-glycerol phosphate; Quench buffer 50 mM HEPES pH 7.3, 16.6 mM EDTA, 0.1% BSA, 0.1% Triton X-100, 0.17 nM labeled monoclonal antibody, 0.0067 mg/mL SA-APC; ATP/MgCl2 working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, active Akt; Peptide working solution: 1X Assay buffer, 1 mM DTT, 1X PIC, 5% glycerol, 2 TM GSK biotinylated peptide. The reaction is assembled by adding 16 µL of ATP/MgCl2 working solution to the appropriate wells. MK-2206 or vehicle (1.0 µL) is added followed by 10 µL of peptide working solution. The reaction is started by adding 13 μL of the enzyme working solution and mixing. The reaction is allowed to proceed for 50 min and then stopped by the addition of 60 µL HTRF quench buffer. The stopped reactions are incubated at room temperature for at least 30 min and then read in the instrument.

Cell Assay: [2]

Cell lines A431, HCC827, NCI-H292, NCI-H358, NCI-H23, NCI-H1299, Calu-6 and NCI-H460 cells
Concentrations 0, 0.3, 1 and 3 μM
Incubation Time 72 or 96 hours
Method MK-2206 is dissolved in DMSO as a stock solution and diluted by culture media before use. Cells are seeded at a density of 2-3 × 103 in 96-well plates and incubated for 24 hours. Then MK-2206 (0, 0.3, 1 and 3 μM) is added to the cells. Cell proliferation is determined after 72 or 96 hours.

Animal Study: [2]

Animal Models SK-OV-3, NCI-H292, HCC70, PC-3, and NCI-H460 models in male CD1-nude mice
Formulation Formulated in 30% Captisol
Dosages 120 mg/kg
Administration Orally administered

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDogMonkeyBaboon
Weight (kg)0.020.151.80.40.0810312
Body Surface Area (m2)0.0070.0250.150.050.020.50.240.6
Km factor361285201220
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Yan L, AACR Annual Meeting 2009: Abstract Number: DDT01-1.

[2] Hirai H, et al. Mol Cancer Therapy, 2010, 9(7), 1956-1967.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2015-06-27)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01802320 Recruiting Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent  ...more Colon Mucinous Adenocarcinoma|Colon Signet Ring Cell Adenocarcinoma|Rectal Mucinous Adenocarcinoma|Rectal Signet Ring Cell Adenocarcinoma|Recurrent Colon Carcinoma|Recurrent Rectal Carcinoma|Stage IIIA Colon Cancer|Stage IIIA Rectal Cancer|Stage IIIB Colon Cancer|Stage IIIB Rectal Cancer|Stage IIIC Colon Cancer|Stage IIIC Rectal Cancer|Stage IVA Colon Cancer|Stage IVA Rectal Cancer|Stage IVB Colon Cancer|Stage IVB Rectal Cancer National Cancer Institute (NCI) March 2013 Phase 2
NCT01783171 Recruiting Pancreatic Adenocarcinoma|Recurrent Pancreatic Carcinoma|Stage III Pancreatic Cancer|Stage IV Pancreatic Cancer|Unresectable Pancreatic Cancer National Cancer Institute (NCI) January 2013 Phase 1
NCT01776008 Recruiting Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|St  ...more Estrogen Receptor Positive|HER2/Neu Negative|Recurrent Breast Carcinoma|Stage IIA Breast Cancer|Stage IIB Breast Cancer|Stage IIIA Breast Cancer|Stage IIIB Breast Cancer|Stage IIIC Breast Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01859182 Withdrawn Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adu  ...more Adenocarcinoma of the Gallbladder|Adenocarcinoma With Squamous Metaplasia of the Gallbladder|Adult Primary Cholangiocellular Carcinoma|Advanced Adult Primary Liver Cancer|Cholangiocarcinoma of the Extrahepatic Bile Duct|Localized Unresectable Adult Primary Liver Cancer|Metastatic Extrahepatic Bile Duct Cancer|Recurrent Adult Primary Liver Cancer|Recurrent Extrahepatic Bile Duct Cancer|Stage II Gallbladder Cancer|Stage IIIA Gallbladder Cancer|Stage IIIB Gallbladder Cancer|Stage IVA Gallbladder Cancer|Stage IVB Gallbladder Cancer|Unresectable Extrahepatic Bile Duct Cancer National Cancer Institute (NCI) January 2013 Phase 2
NCT01705340 Terminated Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|  ...more Adenocarcinoma of the Gastroesophageal Junction|HER2-positive Breast Cancer|Male Breast Cancer|Recurrent Breast Cancer|Recurrent Esophageal Cancer|Recurrent Gastric Cancer|Stage IIIC Breast Cancer|Stage IIIC Esophageal Cancer|Stage IIIC Gastric Cancer|Stage IV Breast Cancer|Stage IV Esophageal Cancer|Stage IV Gastric Cancer National Cancer Institute (NCI) September 2012 Phase 1

view more

Chemical Information

Download MK-2206 2HCl SDF
Molecular Weight (MW) 480.39
Formula

C25H21N5O.2HCl

CAS No. 1032350-13-2
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms N/A
Solubility (25°C) * In vitro DMSO 14 mg/mL (29.14 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 15% Captisol 17 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 8-(4-(1-aminocyclobutyl)phenyl)-9-phenyl-[1,2,4]triazolo[3,4-f][1,6]naphthyridin-3(2H)-one

Customer Product Validation (16)


Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines T-ALL cells
Concentrations 10 uM
Incubation Time 5 h
Results western blot analysis with the AKT phosphorylationmotif antibody showed decreased AKT phosphorylated NR3C1in NR3C1 immunoprecipitates from CCRF-CEM T-ALL cellsupon AKT inhibition with MK2206

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method flow cytometry
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results AKT1 inhibition of CCRF-CEM lymphoblasts with MK2206 effectivelyrestored glucocorticoid-induced apoptosis and reversed glucocorticoid resistance in vitro.

Click to enlarge
Rating
Source Cancer Cell 2013 24, 766-76. MK-2206 2HCl purchased from Selleck
Method analysis of luciferase activity
Cell Lines immunodeficient NOG mice
Concentrations 10 mg kg-1
Incubation Time 3 days
Results In this experiment, animalstreated with dexamethasone or MK2206 showed progressivetumor growth similar to that observed in vehicle-treated controls,while mice treated with MK2206 plus dexamethasone had significant antitumor responses.

Click to enlarge
Rating
Source Cancer Discov 2012 2, 934-47. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines PC9GR4/WZR10 cells
Concentrations 1 uM
Incubation Time 72 h
Results The addition of a dual PI3K and MTOR inhibitor, PI103, or the AKT inhibitor MK-2206, did reduce the expression of pAKT neither in GR4 cells nor WZR10 cells.

Click to enlarge
Rating
Source Cancer Res 2013 73, 2189-98. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines SKNAS/SJNB8/IMR32/GIMEN/SHEP2/KCNR/NGP/LAN1/LAN5/TR14/UHGNP cell lines
Concentrations 8 μM
Incubation Time 48 h
Results The 8 μM MK-2206 treatments resulted in effective pathway inhibition in all cell lines as shown by western blot for phosphoryl ated FOXO3a and PRAS40 as well as AKT serine 473 phosphorylation.

Click to enlarge
Rating
Source Oncotarget 2011 2, 1109-26. MK-2206 2HCl purchased from Selleck
Method Western blot/ Wst-1 assay
Cell Lines ATC/ FTC cell lines
Concentrations 500 nM
Incubation Time 1 h/72 h
Results One-hour treatment with the AKT inhibitor MK-2206 (0.5 μM) or with the MEK inhibitor U0126 (10 μM) effectively abolished AKT and ERK1/2 phosphorylation in all cell lines.

Click to enlarge
Rating
Source Sci Signal 2011 4, rs9. MK-2206 2HCl purchased from Selleck
Method ELISA
Cell Lines HeLa cells
Concentrations 1 μM
Incubation Time
Results Treatment of infected cells with kinase inhibitors directed at Akt (MK-2206), MEK(PD 98059), PKC(CEC), or Pim family kinases identified a dominant role for Pim family kinases in the release of IL-8 from Salmonella-infected epithelial cells.

Click to enlarge
Rating
Source FASEB J 2013 27, 1644-56. MK-2206 2HCl purchased from Selleck
Method Clonogenic growth assay
Cell Lines U2OS cells
Concentrations 1 μM
Incubation Time 9 d
Results Specific inhibition of PKB activity using MK-2206 or triciribine also significantly reduced cell growth, although to a lesser extent compared to PI-103, suggesting that both the PKB and mTOR pathways are important for anchorage-dependent growth.

Click to enlarge
Rating
Source Biochim Biophys Acta 2012 1823, 987-96. MK-2206 2HCl purchased from Selleck
Method Immunofluorescence
Cell Lines HC11 cells
Concentrations 10 µM
Incubation Time 1 h
Results whole ADRP levels, estimated by Western blot , decreased only in the presence of MK -2206 and LY294002. In most cases, ADRP decorated the surface of small lipid droplets and appeared as little patches on large cytoplasmic lipid droplets. With the exception of SP600125, which induced a strong ADRP coating of almost all cytoplasmic lipid droplets (although this inhibitor did not increase ADRP synthesis), variation in the distribution of ADRP at the surface of lipid droplet was difficult to estimate, notably because the signal was faint and uneven.

Click to enlarge
Rating
Source Gynecol Oncol 2011 123, 13-8. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines ovarian cancer cell lines
Concentrations 1-6 μM
Incubation Time 1 h/72 h
Results Activation of pAKT by IGF-1 in the low-grade cell line HOC-7 was blocked by the AKT inhibitor MK-2206.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Confocal microscopy
Cell Lines platelets
Concentrations 1μM
Incubation Time
Results Upon treatment with increasing concentrations of AEA from 0.1 to 10 mM (Fig. B–D) platelets were fully fluorescently marked as compared to control (Fig. A) and the increase in DAF 2 fluorescence intensity appears to be dose-dependent. In agreement with data shown in Figure 4, SR1(Fig. E) and MK2206 (Fig. F) abolished fluorescence intensity induced by AEA, while LY294002 (Fig. 5G) was less potent.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines platelets
Concentrations 1 μM
Incubation Time
Results eNOSser1177 phosphorylation was greatly reduced by LY294002 and cancelled by MK2206 but it was not modified by platelet pretreatment with EGTA or BAPTA/AM.

Click to enlarge
Rating
Source J Cell Biochem 2011 112, 924–932. MK-2206 2HCl purchased from Selleck
Method Nitriter+Nitrate(NOX) measurement, cGMP detection
Cell Lines platelets
Concentrations 1 μM
Incubation Time 1 min
Results As shown in Figure 4 SR1 significantly reduced both NOx and cGMP formation, while SR2 failed to affect these parameters.

Click to enlarge
Rating
Source Radiat Oncol 2009 4, 43. MK-2206 2HCl purchased from Selleck
Method Western blot, clonogenic survival assay
Cell Lines U87MG cells
Concentrations 1 μM
Incubation Time 1 h
Results Akt inhibitor MK-2206 showed similar effect. MK-2206 is a potent allosteric Akt inhibitor with IC50 at 8 nm, 2 mM, 65 mM for Akt1, Akt2 and Akt3 respectively. U87MG cells were preincubated with 1 μM MK-2206 for 1 hr, followed by irradiation at 0 - 9 Gy. As shown in Fig C, MK-2206 treatment abolished IR-induced Akt phosphorylation. Moreover, treatment with MK-2206 also increased the radiosensitivity of U87MGcells (Fig. D)

Click to enlarge
Rating
Source Dr. Zhang of Tianjin Medical University. MK-2206 2HCl purchased from Selleck
Method Western blot
Cell Lines Breast cancer cells
Concentrations 0-10 nM
Incubation Time 3 h
Results Breast cancer cells were serum starved for 24 h, pretreated with the indicated concentrations of MK-2206 for 3 h, and then treated with 100ng/ml EGF for 15 min.

Click to enlarge
Rating
Source MK-2206 2HCl purchased from Selleck
Method Western blot analysis
Cell Lines MCF-7 cells
Concentrations 0 nM/100 nM/250 nM/1000 nM
Incubation Time 24 h
Results The effect of MK-2206 on the serine 473 phosphorylation mark of AKT 1 was uneven and did not correlate with inhibition of AKT activity, but the AKT1 mutant cells maintained higher levels of AKT1 serine 473 phosphorylation with increasing concentrations of MK-2206. Of note, MK-2206 completely inhibited AKT2 activation at 100 nM, a concentration where PIK3CA E545K mutant, but not AKT1 mutant cells were already strongly growth inhibited. MK-2206 treatment up to 1 μM did not have strong effects on other protein biomarkers such as ribosomal protein S6, ev en though growth was suppressed by approximately 80% in MCF-7 cells at this concentration.

Product Use Citation (156)

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Akt Products

  • AT13148

    AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

  • Afuresertib (GSK2110183)

    Afuresertib (GSK2110183) is a potent, orally bioavailable Akt inhibitor with Ki of 0.08 nM, 2 nM, and 2.6 nM for Akt1, Akt2, and Akt3, respectively. Phase 2.

  • LY2090314

    LY2090314 is a potent GSK-3 inhibitor for GSK-3α/β with IC50 of 1.5 nM/0.9 nM; may improve the efficacy of platinum-based chemotherapy regimens. Phase 2.

  • AZD5363

    AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

    Features:Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.

  • GSK690693

    GSK690693 is a pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 2 nM/13 nM/9 nM in cell-free assays, also sensitive to the AGC kinase family: PKA, PrkX and PKC isozymes. Phase 1.

  • Ipatasertib (GDC-0068)

    Ipatasertib (GDC-0068) is a highly selective pan-Akt inhibitor targeting Akt1/2/3 with IC50 of 5 nM/18 nM/8 nM in cell-free assays, 620-fold selectivity over PKA. Phase 2.

  • Perifosine (KRX-0401)

    Perifosine (KRX-0401) is a novel Akt inhibitor with IC50 of 4.7 μM in MM.1S cells, targets pleckstrin homology domain of Akt. Phase 3.

  • A-674563

    A-674563 is an Akt1 inhibitor with Ki of 11 nM in cell-free assays, modest potent to PKA and >30-fold selective for Akt1 over PKC.

    Features:Orally bioavailable compound (achieved by replacing indole of A-443654 with phenyl moiety) and somewhat less selective for Akt over PKA than A-443654.

  • CCT128930

    CCT128930 is a potent, ATP-competitive and selective inhibitor of Akt2 with IC50 of 6 nM in a cell-free assay, 28-fold greater selectivity for Akt2 than the closely related PKA kinase.

  • Triciribine

    Triciribine is a DNA synthesis inhibitor, also inhibits Akt in PC3 cell line and HIV-1 in CEM-SS, H9, H9IIIB, U1 cells with IC50 of 130 nM and 20 nM, respectively; does not inhibit PI3K/PDK1; 5000-fold less active in cells lack

Recently Viewed Items

Tags: buy MK-2206 2HCl | MK-2206 2HCl supplier | purchase MK-2206 2HCl | MK-2206 2HCl cost | MK-2206 2HCl manufacturer | order MK-2206 2HCl | MK-2206 2HCl distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description
Contact Us